Anthera – $15 Million Shelf-Takedown Offering

San Francisco – March 22, 2017 – Cooley advised the underwriter on Anthera’s $15 million shelf-takedown offering of 30,000,000 shares of common stock and two tranches of warrants to purchase up to an aggregate of 60,000,000 shares. The underwriter has a 30-day option to purchase up to an additional 4,500,000 shares of common stock and/or warrants to purchase up to an additional 9,000,000 shares of common stock at the public offering prices.

Rodman & Renshaw, a unit of HC Wainwright & Co., acted as the sole book-running manager for the offering.

Anthera, which trades on The NASDAQ Global Market as “ANTH,” is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.